[논문]Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients

Kim, Jung Sun; Park, In Hae; Lee, Keun Seok; Ro, Jungsil

doi:10.4048/jbc.2014.17.4.339

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients 원문보기

Journal of breast cancer= 한국유방암학회지, v.17 no.4, 2014년, pp.339 - 343

Kim, Jung Sun (Center for Breast Cancer, National Cancer Center, Goyang, Korea.) , Park, In Hae (Center for Breast Cancer, National Cancer Center, Goyang, Korea.) , Lee, Keun Seok (Center for Breast Cancer, National Cancer Center, Goyang, Korea.) , Ro, Jungsil (Center for Breast Cancer, National Cancer Center, Goyang, Korea.)

Abstract ▼ AI-Helper

PurposeThe combination of gemcitabine and cisplatin (GP) has been shown to be safe and efficacious for patients with metastatic breast cancer (MBC), pretreated with anthracyclines and taxanes. We assessed the efficacy and safety of weekly low-dose GP in patients with MBC.MethodsWe collected clinicopathological data from MBC patients who had been treated with gemcitabine, 800 mg/m2 plus cisplatin, 30 mg/m2 intravenously, on days 1 and 8 every 3 weeks, between January 2001 and November 2011 in Korea.ResultsThe analysis included 294 patients previously treated anthracycline-xand taxane-based chemotherapies prior to GP (median age, 48 years [range, 28-78 years]; median follow-up duration, 63.9 months). Seventeen patients (5.8%) discontinued GP because of toxicities. The median progression-free survival (PFS) was 3.9 months (95% confidence interval [CI], 3.394.4 months) and the median overall survival (OS) was 27.7 months (95% CI, 17.6-37.8 months) months. Statistically significant factors for PFS were performance status (Eastern Cooperative Oncology Group, ≥2 vs. <2; hazard ratio [HR], 1.37; 95% CI, 1.02-1.85; p=0.037), distant disease-free interval (DDFI; ≤2 years vs. >2 years; HR, 1.66; 95% CI, 1.28-1.95, p1 year; HR, 1.48; 95% CI, 1.13-1.95, p<0.001), and presence of brain metastasis (HR, 1.47; 95% CI, 1.03-2.10; p=0.031). Similarly, DDFI (≤2 years vs. >2 years; HR, 2.07; 95% CI, 1.36-3.14; p<0.001) and the presence of brain metastasis (HR, 2.14; 95% CI, 1.27-3.61; p=0.004) were important factors for OS after GP treatment.ConclusionWeekly low-dose GP chemotherapy appears safe and effective for heavily pretreated MBC patients.

주제어

참고문헌 (21)

1 Jung KW Won YJ Kong HJ Oh CM Seo HG Lee JS Cancer statistics in Korea: incidence, mortality, survival and prevalence in 2010 Cancer Res Treat 2013 45 1 14 23613665

상세보기
2 Wirk B Perez E Role of gemcitabine in breast cancer management: an update Semin Oncol 2006 33 1 Suppl 2 S6 S14 16472712
3 De Laurentiis M Cancello G D'Agostino D Giuliano M Giordano A Montagna E Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials J Clin Oncol 2008 26 44 53 18165639

상세보기
4 Ozkan M Berk V Kaplan MA Benekli M Coskun U Bilici A Gemcitabine and cisplatin combination chemotherapy in triple negative metastatic breast cancer previously treated with a taxane/anthracycline chemotherapy; multicenter experience Neoplasma 2012 59 38 42 22103897

상세보기
5 Rha SY Moon YH Jeung HC Kim YT Sohn JH Yang WI Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer Breast Cancer Res Treat 2005 90 215 221 15830134

상세보기
6 Murphy CG Seidman AD Evolving approaches to metastatic breast cancer previously treated with anthracyclines and taxanes Clin Breast Cancer 2009 9 Suppl 2 S58 S65 19596644
7 Heinemann V Gemcitabine plus cisplatin for the treatment of metastatic breast cancer Clin Breast Cancer 2002 3 Suppl 1 24 29 12057042
8 Giovannetti E Danesi R Mey V Nannizzi S Pasqualetti G Del Tacca M In vitro studies on gemcitabine combinations with other antiblastics Ann Oncol 2006 17 Suppl 5 v17 v19 16807450
9 Sledge GW Jr Loehrer PJ Sr Roth BJ Einhorn LH Cisplatin as first-line therapy for metastatic breast cancer J Clin Oncol 1988 6 1811 1814 3199166

상세보기
10 Koshy N Quispe D Shi R Mansour R Burton GV Cisplatin-gemcitabine therapy in metastatic breast cancer: improved outcome in triple negative breast cancer patients compared to non-triple negative patients Breast 2010 19 246 248 20227277

상세보기
11 Hastak K Alli E Ford JM Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly (ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin Cancer Res 2010 70 7970 7980 20798217
12 Seo JH Oh SC Choi CW Kim BS Shin SW Kim YH Phase II study of a gemcitabine and cisplatin combination regimen in taxane resistant metastatic breast cancer Cancer Chemother Pharmacol 2007 59 269 274 16763791

상세보기
13 Kim JH Oh SY Kwon HC Lee S Kim SH Kim DC Phase II study of gemcitabine plus cisplatin in patients with anthracycline- and taxane-pretreated metastatic breast cancer Cancer Res Treat 2008 40 101 105 19688114

상세보기
14 Brito LG de Andrade JM Lins-Almeida T Zola FE Pinheiro MN Marana HR Safety and efficacy of gemcitabine plus cisplatin combination in pretreated metastatic breast cancer patients Med Oncol 2012 29 33 38 21264546

상세보기
15 Weigelt B Peterse JL van't Veer LJ Breast cancer metastasis: markers and models Nat Rev Cancer 2005 5 591 602 16056258

상세보기
16 Gonçalves A Esterni B Bertucci F Sauvan R Chabannon C Cubizolles M Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy Oncogene 2006 25 981 989 16186794

상세보기
17 Wang T Zhang S Zeng M Lu X Shen G Wu S Gemcitabine and cisplatin combination regimen in patients with anthracycline- and taxane-pretreated metastatic breast cancer Med Oncol 2012 29 56 61 21264537

상세보기
18 Sánchez-Escribano Morcuende R Alés-Martínez JE Aramburo González PM Low dose gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens Clin Transl Oncol 2007 9 459 464 17652060

상세보기
19 Muss HB Targeted therapy for metastatic breast cancer N Engl J Med 2006 355 2783 2785 17192546
20 Foulkes WD Smith IE Reis-Filho JS Triple-negative breast cancer N Engl J Med 2010 363 1938 1948 21067385

상세보기
21 Erten C Demir L Somali I Alacacioglu A Kucukzeybek Y Akyol M Cisplatin plus gemcitabine for treatment of breast cancer patients with brain metastases: a preferential option for triple negative patients? Asian Pac J Cancer Prev 2013 14 3711 3717 23886170

원문보기 상세보기

LOADING...

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (21)

이 논문을 인용한 문헌

연구과제 타임라인

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트

연합인증

Outcomes of Palliative Weekly Low-Dose Gemcitabine-Cisplatin Chemotherapy in Anthracycline- and Taxane- Pretreated Metastatic Breast Cancer Patients 원문보기

Abstract ▼ AI-Helper

주제어

참고문헌 (21)

이 논문을 인용한 문헌

연구과제 타임라인

전체(0) 논문(0) 특허(0) 보고서(0)

전체(0) 논문(0) 특허(0) 보고서(0)

관련 콘텐츠

원문 보기

원문 URL 링크

오픈액세스(OA) 유형

이 논문과 함께 이용한 콘텐츠

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

선택된 텍스트